<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ofloxacin (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ofloxacin (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ofloxacin (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12272" href="/d/html/12272.html" rel="external">see "Ofloxacin (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16032" href="/d/html/16032.html" rel="external">see "Ofloxacin (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9496286"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve ofloxacin for use in patients who have no alternative treatment options for the following indications: acute exacerbation of chronic bronchitis and acute uncomplicated cystitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myasthenia gravis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients with a known history of myasthenia gravis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9498132"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Fluoroquinolone</li></ul></div>
<div class="block doa drugH1Div" id="F9497845"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f911986-9700-4a01-ad97-19a378bbbcc4">Epididymitis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epididymitis, acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Likely caused by enteric organisms:</i>
<b>Oral:</b> 200 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34009058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34009058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Likely caused by sexually transmitted chlamydia and gonorrhea, and enteric organisms (patients who practice insertive anal sex):</i>
<b>Oral: </b>200 mg twice daily for 10 days in combination with ceftriaxone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34009058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34009058'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Y. pestis</i>), (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis: </i>
<b>Oral:</b> 400 mg every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, excluding meningitis</i>: <b>Oral:</b> 400 mg every 12 hours for 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired: Oral:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fd32e36-aea8-4922-9fc3-8f98fc89d1d8">Prostatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis:</b>
<b>Oral:</b> 300 mg every 12 hours for 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cervicitis/urethritis due to Chlamydia trachomatis:</i>
<b>Oral:</b> 300 mg every 12 hours for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease, outpatient therapy, mild to moderate disease (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve fluoroquinolones for patients who cannot use first-line options and are at low risk for fluoroquinolone-resistant <i>Neisseria gonorrhoeae</i> (eg, prevalence is &lt;5% in the location where the infection was acquired) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>400 mg every 12 hours for 10 to 14 days. Guidelines recommend use of a fluoroquinolone in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd705302-04a3-41a9-ae4b-6351f8cd05b4">Skin and soft tissue infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, uncomplicated:</b>
<b>Oral:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Treat for 5 to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24d89c6a-0650-459e-92e2-5e1ccda1fe60">Typhoid and paratyphoid fever, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid and paratyphoid fever (<i>S. typhi</i> or <i>S. paratyphi</i> infection), uncomplicated, treatment (off-label use): Note:</b> Use only if <b>
<b>minimum inhibitory concentration </b></b>≤0.125 mcg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22752519','lexi-content-ref-21713025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22752519','lexi-content-ref-21713025'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24282626','lexi-content-ref-17145784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24282626','lexi-content-ref-17145784'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated</i>
<i> or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use is discouraged due to safety concerns and increasing resistance; reserve for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26926640','lexi-content-ref-FDA.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26926640','lexi-content-ref-FDA.1','lexi-content-ref-21292654'])">Ref</a></span>). However, for men who have severe symptoms or there is concern for early prostate involvement, some experts prefer fluoroquinolones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>200 mg every 12 hours for 3 days (females) or 5 days (males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-10190377','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-10190377','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated </i>
<i>(including pyelonephritis):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If the prevalence of fluoroquinolone resistance is &gt;10%, an initial dose of a long-acting parenteral antimicrobial (eg, ceftriaxone) followed by oral therapy is recommended for outpatients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>200 mg every 12 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment </b>
<b>for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991302"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Oral: After a normal initial dose, adjust as follows:</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 20 to 50 mL/minute: Administer usual recommended dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;20 mL/minute: Administer half the usual recommended dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent hemodialysis (IHD): 100 to 200 mg after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: 200 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous renal replacement therapy (CRRT): 300 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988624"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (eg, cirrhosis with or without ascites): Maximum dose: 400 mg/day</p></div>
<div class="block doe drugH1Div" id="F9497846"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812612"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16032" href="/d/html/16032.html" rel="external">see "Ofloxacin (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection: </b>Limited data available: Children: Oral: 15 mg/kg/day divided every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10917383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10917383'])">Ref</a></span>); usual adult dose: 200 to 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70074523-ef25-455b-b94d-8197c3581369">Chlamydia trachomatis anogenital tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chlamydia trachomatis anogenital tract infection:</b> Limited data available: Children weighing ≥45 kg and Adolescents: Oral: 300 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75ef1756-eeb2-4655-aaf1-a9706bf933d2">Epididymitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epididymitis:</b> Likely caused by enteric organisms (eg, <i>Escherichia coli</i>) in males who practice insertive anal sex: Children weighing ≥45 kg and Adolescents: Limited data available: Oral: 300 mg every 12 hours for 10 days in combination with ceftriaxone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease (alternative therapy): </b>Children weighing ≥45 kg and Adolescents: Limited data available: Oral: 400 mg every 12 hours for 10 to 14 days in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.2018'])">Ref</a></span>). <b>Note:</b> The CDC recommends use only if standard cephalosporin therapy is not feasible (patients with severe cephalosporin allergy) and community prevalence of quinolone-resistant gonococcal organisms is low. Culture and susceptibility must be confirmed, and patient follow-up should be ensured (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729800"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment is suggested.</p></div>
<div class="block dohp drugH1Div" id="F52729801"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations. Based on experience in adult patients, dosage adjustment is suggested in patients with severe impairment.</p></div>
<div class="block adr drugH1Div" id="F9497559"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed may be based on reports for other agents in this same pharmacologic class (quinolones) and may not be specifically reported for ofloxacin.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1% to 3%), skin rash (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (1% to 3%), abdominal pain (1% to 3%), constipation (1% to 3%), decreased appetite (1% to 3%), diarrhea (1% to 4%), dysgeusia (1% to 3%), flatulence (1% to 3%), gastrointestinal distress (1% to 3%), nausea (3% to 10%), vomiting (1% to 4%), xerostomia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital pruritus (female: 1% to 6%), vaginal discharge (1% to 3%), vaginitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 5%), drowsiness (1% to 3%), fatigue (1% to 3%), headache (1% to 9%), insomnia (3% to 7%), nervousness (1% to 3%), sleep disorder (1% to 3%), torso pain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, hypotension, palpitations, syncope, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, increased thirst, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, dysuria, genital pain (female), genital rash (female), urinary frequency, urinary retention, uterine hemorrhage, vulvovaginal burning, vulvovaginal irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anxiety, asthenia, chills, cognitive dysfunction, confusion, depression, euphoria, malaise, pain, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, epistaxis, rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria, hematuria, proteinuria, pyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, eosinophilia, increased erythrocyte sedimentation rate, leukocytosis, leukopenia, lymphocytopenia, lymphocytosis, neutropenia, neutrophilia, thrombocytopenia, thrombocythemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Exacerbation of myasthenia gravis, increased intracranial pressure, peripheral neuropathy (including axonal peripheral polyneuropathy, dysesthesia, hypoesthesia, sensorimotor neuropathy, and sensory peripheral polyneuropathy), psychiatric signs and symptoms (including agitation, delirium, disorientation, disturbance in attention, memory impairment, restlessness, and toxic psychosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rupture of tendon, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased urine specific gravity, increased blood urea nitrogen, increased serum creatinine, increased urine pH</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (Guay 1992), torsades de pointes, vasculitis (Pace 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (Nettis 2002), maculopapular rash (Guay 1992), Stevens-Johnson syndrome, toxic epidermal necrolysis (Yoon 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes insipidus (Bharani 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea, dyspepsia (Wilton 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, pancytopenia, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis, hepatitis (Jones 1997), hepatotoxicity (idiosyncratic) (Chalasani 2014), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity angiitis (Ceyhan 1995), hypersensitivity reaction (Wilton 1996), serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hallucination (Wilton 1996), paresthesia (Guay 1992), tremor (Wilton 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (Guay 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, interstitial nephritis, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypersensitivity pneumonitis</p></div>
<div class="block coi drugH1Div" id="F9497548"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ofloxacin, other quinolones, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F9497549"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with a history of QTc prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic aneurysm and dissection: Fluoroquinolones have been associated with aortic aneurysm ruptures or dissection within 2 months following use, particularly in elderly patients. Fluoroquinolones should not be used in patients with a known history of aortic aneurysm or those at increased risk, including patients with peripheral atherosclerotic vascular diseases, hypertension, genetic disorders involving blood vessel changes (eg, Marfan syndrome, Ehlers-Danlos syndrome), and elderly patients, unless no other treatment options are available. Longer treatment duration (eg, &gt;14 days) may increase risk (Lee 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), dizziness, lightheadedness, and tremors. Use with caution in patients with known or suspected CNS disorders (eg, severe cerebral arteriosclerosis, epilepsy) or other risk factors that may predispose to seizures or lower the seizure threshold.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose regulation: Fluoroquinolones have been associated with disturbances in glucose regulation, including hyperglycemia and hypoglycemia. These events have occurred most often in patients receiving concomitant oral hypoglycemic agents or insulin. Severe cases of hypoglycemia, including coma and death, have been reported. Diabetic patients should be monitored closely for signs/symptoms of disordered glucose regulation. Discontinue if a hypoglycemic reaction occurs and immediately initiate appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe, sometimes fatal, hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Peripheral neuropathy has been reported (rare); may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate to severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric reactions: Fluoroquinolones have been associated with an increased risk of psychiatric reactions, including toxic psychosis or hallucinations; may also cause nervousness, agitation, confusion, disorientation, delirium, attention disturbances, and memory impairment. Use with caution in patients with a history of or risk factor for depression; discontinue if reaction occurs and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syphilis: Since ofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later. <b>Note:</b> As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency (Luzzatto 2020).</p></div>
<div class="block foc drugH1Div" id="F9497986"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F9496347"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9497988"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ofloxacin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $14.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $19.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869679"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 300 mg, 400 mg</p></div>
<div class="block adm drugH1Div" id="F9497866"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Administer with or without food. Do not take within 2 hours of sucralfate, didanosine, iron, zinc, or antacids containing magnesium, calcium, or aluminum. </p></div>
<div class="block admp drugH1Div" id="F52614389"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food.</p></div>
<div class="block meg drugH1Div" id="F9496293"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088599.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlmzuJ2%2BfbdxZtYfgShrzKFg%3D%3D&amp;TOPIC_ID=9892" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F9496348"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, skin and soft tissue infections (uncomplicated), urethritis and cervicitis (nongonococcal) due to <i>Chlamydia trachomatis</i> infection, pelvic inflammatory disease (acute), cystitis (uncomplicated), urinary tract infections (complicated), prostatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Because fluoroquinolones, including ofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinopathy and tendon rupture, peripheral neuropathy, CNS effects), reserve ofloxacin for use in patients who have no alternative treatment options for uncomplicated urinary tract infection and for acute exacerbations of chronic bronchitis when treatment is necessary (FDA 2016).</p></div>
<div class="block off-label drugH1Div" id="F25730957"><span class="drugH1">Use: Off-Label: Adult</span><p>Epididymitis, acute; Plague (Yersinia pestis); Typhoid and paratyphoid fever (Salmonella typhi or S. parathyphi infection), uncomplicated, treatment</p></div>
<div class="block cyt drugH1Div" id="F9497653"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F9497654"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone; see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use if possible. If coadministration is unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased quinolone efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of quinolones.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F9496355"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of teratogenic effects has not been observed following ofloxacin use during pregnancy (Padberg 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Serum concentrations of ofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989).</p>
<p style="text-indent:0em;margin-top:2em;">Ofloxacin is used in the management of plague (<i>Y. pestis</i>). Untreated infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis</i>; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Ofloxacin is an alternative fluroquinolone recommended for use (in combination with an aminoglycoside) for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Ofloxacin may also be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis </i>(CDC [Nelson 2021]).</p></div>
<div class="block brc drugH1Div" id="F9497547"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ofloxacin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Following administration of ofloxacin 200 mg as a single oral dose, breast milk concentrations were similar to those in the maternal plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Ofloxacin is used in the management of plague (<i>Y. pestis</i>). The risk for transmission of <i>Y. pestis</i> via breast milk is considered low. Patients with pneumonic plague can breastfeed if both the mother and infant are receiving antibiotic treatment or the infant is receiving postexposure prophylaxis, considering the risk of exposure to the drug via breast milk. If the infant is not being treated, breast milk should be expressed for at least 48 hours of maternal antibiotic therapy to limit person-to-person contact with the infant. The expressed breast milk may be given to the infant. Once maternal clinical improvement is observed, direct breastfeeding may resume. Patients taking ofloxacin for the treatment of plague can decrease infant exposure via breast milk by feeding 4 to 6 hours after the dose (CDC [Nelson 2021]).</p></div>
<div class="block mop drugH1Div" id="F15577087"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor CBC, renal and hepatic function periodically if therapy is prolonged; signs and symptoms of disordered glucose regulation.</p></div>
<div class="block pha drugH1Div" id="F9497678"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal.</p></div>
<div class="block phk drugH1Div" id="F9497680"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed into body tissues and fluids, including blister fluid, cervix, lung, ovary, prostatic tissue, skin, and sputum ; V<sub>d</sub>: 2.4 to 3.5 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 32%.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~9 hours (biphasic: 4 to 5 hours [6.4 to 7.4 hours in elderly patients] and 20 to 25 hours [accounts for &lt;5%]); prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 65% to 80% (as unchanged drug); feces: 4% to 8%; &lt;10% is metabolized.</p></div>
<div class="block phksp drugH1Div" id="F51154906"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced in patients with CrCl &lt;50 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961995"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Floxil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Flocet | Oflacin | Tariflox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Asmoflox | Ocet | Oflomac | Quinolox | Umeflox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ofloxin | Tarivid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Floxina | Floxstat | Ofloxacino | Ofloxan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Ocet | Oflocare | Ofloxacine tm | Ofloxyl | Oflozix | Quinolox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">AN FU LE | An li | Ao fu xing | Bei li de | Kang tai bi tuo | Ofloxacin | She yue | Tarivid | Xin li tuo | Ya fu xing | Yang wei | Zan nuo xin | Zanocin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ofloxacino altan | Ofloxacino g.e.s. | Ofloxin | Tarivid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ofloxacin Ratiopharm | Tarivid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Floxstat | Grenis Oflo | Maxifloxina | Quinoflox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Floxstat | Microbac | Ofloxacino | Oxiflox | Urostat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ermofan | Medofloxine | Ofloxin | Tarivid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kiroll | Ofloxin | Tariflox | Tarivan | Tarivid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Oflovir | Ofloxacino g.e.s. | Surnox | Tarivid</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ofloxacine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oflocet | Ofloxacine Aguettant | Ofloxacine maco pharma | Ofloxacine merck | Ofloxacine merck generiques | Ofloxacine pfizer</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tabrin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-Ofloxacin | Flovid | Gyrolf | Ofla | Ofloxal | Quotavil | Tarivid | Viotisone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Betaflox | Floxika | Hexaflox | Occidal | Ofloxacin | Ofloxin | Poncoquin | Rilox | Tariflox | Tarivid | Zelavel | Zyflox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Buravid | Tarivid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ofloxacin Teva | Tarivid | Uro Tarivid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Agroflox | Alof | Alproxen | Anzocin | Aqlox | Axaflox | Bacter | Bactorax | Bestoflox | Bidflox | Bidoflox | Bio Flo | Bioff | Cadof | Canoxcin | Curadex | Digaflox | Dioflox | Doact | Elox | Eufox | Exvid | Feno | Flox | Floxagen | Floxet | Floxicontin-O | Floxiquin | Floxo plus | Floxur | Foxcin | Galoxin | Gazflox | Genflox | Harpoon | Kimflox | Klof | Magof | Manocin | Max O Flox | Mexaflo | Moflox | Nicaxo | Novofran | Nuflexin | O Fane | O Quin | O-cebran | Obact | Ocin | Ocinc | Of | Ofal | Ofax | Ofcret | Off | Offmark | Oflabin | Oflacin | Oflakem | Oflamed | Oflank | Oflatoon | Oflax | Oflem | Ofler | Oflin | Oflo | Oflobid | Oflocare | Oflocon | Oflodex | Oflomac | Ofloren | Oflores | Oflostar | Oflosun | Oflotas | Ofloter | Oflox | Ofloxain | Ofloxal | Ofloxamac | Oflozen | Ofnij | Ofo | Ofslog | Ofuxin | Ofvista | Ofzen | Okaflox | Olaxi | Olfi | Olife | Omet | Onilox | Onofbact | Onoff | Oq | Oraflox | Oson | Otox | Ozoflox | Qubid | Quinoflox | Quinox | Riviflox | Ronflox | Srflox | Supaxin | Tariflox | Tarivid | Toflox | Troflox | Wisoflox | Zanocin | Zanoflox | Zanovid | Zenflox | Zerocin | Zo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Flobacin | Oflocin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Novecin | Tarivid</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Oflan | Oflo | Oflobid | Oflomac | Ofloxacin uf | Sunflox | Tarivid | Zofex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Effexin | Ofla</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Novecin | Tarivid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo Oflox | Oflacin | Oflomed | Tarivid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ofloxin | Tarivid | Zanocin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Medofloxine | Ofloxin | Tarivid | Zanocin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Floximat | Oflocet | Oloxine | Oxiflor | Quinolox | Tarivid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bactocin | Flonacin | Flosep | Floxil | Floxstat | Ibacnol | Ofloxacina | Ofloxacina Raam | Ofloxacino | Oxken | Quiflural | Rixivoc</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Inoflox | Medofloxine | Oflicin | Oflicin-100 | Oflicin-200 | Prifloxin | Tarivid</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bgvid | Chazmax ofloxacin | Coravid | Drovid | Jozza | Jvi ofloxacin | Maco ofloxacin | Marley ofloxacin | Mevid | New divine ofloxacin | Offlo | Oflasyn | Oflolem | Oflomed | Ofloxalab | Ofloxamet | Oniflo | Pauco ofloxacin | Radoflox | Tatatab</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Flodemex | Flotaz | Flovid | Floxy | Gyrex | Gyros | Inoflox | Itex | Lumflox | Mergexin | Oxyflox | Prozu | Qinolon | Syfloxacin | Terioxan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A vid | Adios | Albact | Alcin | Arvid | Avocin | Axaflox | Bacteflox | Curitol | Dyramid | Ecoflox | Ecolox | Emevid | Euvid | Florax | Floxy | Fugacin | Furacin | G Vid | Geoflox | Gyrasid | Joxacin | Korvid | Lebx | Loxat | Loxpro | Lutiflox | O Quine | Ofaxin ds | Oflamed | Oflan | Oflatain | Oflaxa-Z | Oflobid | Oflocin | Ofloquin | Ofloscot | Oftin | Olax | Oracin | Oxiflox | Quinox | Qulavid | Rekoflox | Salmocin | Shaflo | T-vid | Tabroxacin | Tariflox | Taripharm | Tarivid | Tissot | Triva | Unox | Visoflox | Wiloxin | Wiloxovid | Zanacin | Zoxam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Oflodinex | Tarivid | Zanocin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Floxin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bactoflox | Megasin | Oflocet | Ofloxacina | Tarivid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Novecin | Tarivid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ofloxin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ashof | Flosiprin | Jeoflox | Oflo | Ofloxabol | Ofloxacin | Ofloxacin protech | Ofloxacin zentiva | Ofloxacin-akos | Ofloxacin-fpo | Ofloxin | Roflo | Tarivid | Zanocin | Zoflox</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Inoflox | Tarivid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Medofloxine | Ofloxin | Tarivid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Oflo | Oflocet | Ofloject | Ofloxine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Girasid | Menefloks | Tarivid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tarivid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Floksan | Geoflox | Oflobac | Ofloxacin | Ofloxacin Kmp | Ofloxin | Tarivid | Zanocin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Oflin | Ofloxacin uf | Orav | Toflox | Zofex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Floxstat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-ofloxacin | Tarivid</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Evaflox | Ofloxin | Ofoxin | Ole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Abramowicz.1">
<a name="Abramowicz.1"></a>Abramowicz M, “Antimicrobial Prophylaxis in Surgery,” <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10917383">
<a name="10917383"></a>Alghasham AA and Nahata MC, “Clinical Use of Fluoroquinolones in Children,” <i>Ann Pharmacother</i>, 2000, 34(3):347-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/10917383/pubmed" id="10917383" target="_blank">10917383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20496567">
<a name="20496567"></a>Balagon MF, Cellona RV, Abalos RM, Gelber RH, Saunderson PR. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy. <i>Lepr Rev</i>. 2010;81(1):27-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/20496567/pubmed" id="20496567" target="_blank">20496567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926640">
<a name="26926640"></a>Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? <i>Antimicrob Agents Chemother</i>. 2016;60(5):3170-3173. doi:10.1128/AAC.02505-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/26926640/pubmed" id="26926640" target="_blank">26926640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17431378">
<a name="17431378"></a>Centers for Disease Control and Prevention, “Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,” <i>MMWR Recomm Rep</i>, 2007, 56(14):332-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/17431378/pubmed" id="17431378" target="_blank">17431378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34009058">
<a name="34009058"></a>Chirwa M, Davies O, Castelino S, et al. United Kingdom British association for sexual health and HIV national guideline for the management of epididymo-orchitis, 2020. <i>Int J STD AIDS</i>. 2021;32(10):884-895. doi:10.1177/09564624211003761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/34009058/pubmed" id="34009058" target="_blank">34009058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15585448">
<a name="15585448"></a>Friedrich LV and Dougherty R, “Fatal Hypoglycemia Associated With Levofloxacin,” <i>Pharmacotherapy</i>, 2004, 24(12):1807-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15585448/pubmed" id="15585448" target="_blank">15585448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16206101">
<a name="16206101"></a>Frothingham R, “Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,” <i>Clin Infect Dis</i>, 2005, 41(9):1269-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16206101/pubmed" id="16206101" target="_blank">16206101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15230648">
<a name="15230648"></a>Gavin JR 3rd, Kubin R, Choudhri S, et al, “Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,” <i>Drug Saf</i>, 2004, 27(9):671-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15230648/pubmed" id="15230648" target="_blank">15230648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589353">
<a name="2589353"></a>Giamarellou H, Kolokythas E, Petrikkos G, et al. "Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women," Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/2589353/pubmed" id="2589353" target="_blank">2589353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185172">
<a name="16185172"></a>Graumlich JF, Habis S, Avelino RR, et al, “Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,” <i>Pharmacotherapy</i>, 2005, 25(10):1296-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16185172/pubmed" id="16185172" target="_blank">16185172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17109284">
<a name="17109284"></a>Hill DR, Ericsson CD, Pearson RD, et al; The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <i>Clin Inf Dis</i>. 2006;43(12):1499-1539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/17109284/pubmed" id="17109284" target="_blank">17109284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22752519">
<a name="22752519"></a>Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. <i>Clin Infect Dis</i>. 2012;55(8):1107-1113. doi:10.1093/cid/cis600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/22752519/pubmed" id="22752519" target="_blank">22752519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jacobs.1">
<a name="Jacobs.1"></a>Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: Susceptibility of Pathogens Isolated From Community-Acquired Respiratory Tract Infection to Commonly Used Antimicrobial Agents. <i>J Antimicrob Chemother</i>. 2003;52(2):229-246.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766835">
<a name="12766835"></a>Khaliq Y, Zhanel GG. Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature. <i>Clin Infect Dis</i>. 2003;36(11):1404-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/12766835/pubmed" id="12766835" target="_blank">12766835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24282626">
<a name="24282626"></a>Koirala S, Basnyat B, Arjyal A, et al. Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. <i>PLoS Negl Trop Dis</i>. 2013;7(10):e2523. doi:10.1371/journal.pntd.0002523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24282626/pubmed" id="24282626" target="_blank">24282626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16269178">
<a name="16269178"></a>Lawrence KR, Adra M, Keir C. Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin. <i>J Infect</i>. 2006;52(6):e177-e180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16269178/pubmed" id="16269178" target="_blank">16269178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30213330">
<a name="30213330"></a>Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. <i>J Am Coll Cardiol</i>. 2018;72(12):1369-1378. doi:10.1016/j.jacc.2018.06.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/30213330/pubmed" id="30213330" target="_blank">30213330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624471">
<a name="9624471"></a>Loebstein R, Addis A, Ho E, et al. Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study. <i>Antimicrob Agents Chemother</i>. 1998;42(6):1336-1339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9624471/pubmed" id="9624471" target="_blank">9624471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702756">
<a name="32702756"></a>Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Blood</i>. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/32702756/pubmed" id="32702756" target="_blank">32702756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557500">
<a name="11557500"></a>Malone RS, Fish DN, Abraham E, et al, “Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,” <i>Antimicrob Agents Chemother</i>, 2001, 45(10):2949-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/11557500/pubmed" id="11557500" target="_blank">11557500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23484334">
<a name="23484334"></a>Manickam P, Nagaraju B, Selvaraj V, et al. Team of Study Investigators. Efficacy of single-dose chemotherapy (rifampicin, ofloxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial. <i>Indian J Lepr</i>. 2012;84(3):195-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/23484334/pubmed" id="23484334" target="_blank">23484334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10190377">
<a name="10190377"></a>McCarty JM, Richard G, Huck W, et al; Ciprofloxacin Urinary Tract Infection Group. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. <i>Am J Med</i>. 1999;106(3):292-299. doi:10.1016/s0002-9343(99)00026-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/10190377/pubmed" id="10190377" target="_blank">10190377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al; American Thoracic Society; Infectious Diseases Society of America. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med.</i> 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185173">
<a name="16185173"></a>Mohr JF, McKinnon PS, Peymann PJ, et al. A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone. <i>Pharmactherapy</i>. 2005;25(10):1303-1309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16185173/pubmed" id="16185173" target="_blank">16185173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al; Contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1794020">
<a name="1794020"></a>Nilsson-Ehle I, Ljungberg B. Quinolone Disposition in the Elderly: Practical Implications. <i>Drugs Aging</i>. 1991;1(4):279-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/1794020/pubmed" id="1794020" target="_blank">1794020</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ofloxacin tablets [prescribing information]. Canton, MS: Larken Laboratories Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24841264">
<a name="24841264"></a>Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24841264/pubmed" id="24841264" target="_blank">24841264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16510739">
<a name="16510739"></a>Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults. <i>N Engl J Med</i>. 2006;354(13):1352-1361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16510739/pubmed" id="16510739" target="_blank">16510739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17145784">
<a name="17145784"></a>Parry CM, Ho VA, Phuong le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. <i>Antimicrob Agents Chemother</i>. 2007;51(3):819-825. doi:10.1128/AAC.00447-06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/17145784/pubmed" id="17145784" target="_blank">17145784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21713025">
<a name="21713025"></a>Parry CM, Vinh H, Chinh NT, et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. <i>PLoS Negl Trop Dis</i>. 2011;5(6):e1163. doi:10.1371/journal.pntd.0001163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/21713025/pubmed" id="21713025" target="_blank">21713025</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. <i>J Clin Pharmacol</i>. 2016;56(9):1060-1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/26865283/pubmed" id="26865283" target="_blank">26865283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1763532">
<a name="1763532"></a>Peled Y, Friedman S, Hod M, et al. Ofloxacin During the Second Trimester of Pregnancy. <i>DICP</i>. 1991;25(11):1181-1182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/1763532/pubmed" id="1763532" target="_blank">1763532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068718">
<a name="27068718"></a>Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi:10.1038/ajg.2016.126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/27068718/pubmed" id="27068718" target="_blank">27068718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21914093">
<a name="21914093"></a>Setia MS, Shinde SS, Jerajani HR, et al. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. <i>Trop Med Int Health</i>. 2011;16(12):1541-1551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/21914093/pubmed" id="21914093" target="_blank">21914093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et all. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Szarfman.1">
<a name="Szarfman.1"></a>Szarfman A, Chen M, Blum MD. More on Fluoroquinolone Antibiotics and Tendon Rupture. <i>N Engl J Med</i>. 1995;332(3):193.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9774127">
<a name="9774127"></a>Thalhammer F, Kletzmayr J, El Menyawi I, et al. Ofloxacin Clearance During Hemodialysis: A Comparison of Polysulfone and Cellulose Acetate Hemodialyzers. <i>Am J Kidney Dis</i>. 1998;32(4):642-645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9774127/pubmed" id="9774127" target="_blank">9774127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i> Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm</a>. Published May 12, 2016. Accessed November 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Dept. Health and Human Services. National Hansen's Disease Program: Recommended treatment regimens. <a href="https://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html" target="_blank">http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14993633">
<a name="14993633"></a>Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. <i>Am J Trop Med Hyg</i>. 2004;70(2):197-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/14993633/pubmed" id="14993633" target="_blank">14993633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16775443">
<a name="16775443"></a>Wang S and Rizvi AA, “Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,” <i>Am J Med Sci</i>, 2006, 331(6):334-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16775443/pubmed" id="16775443" target="_blank">16775443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiesenfeld.2021">
<a name="Wiesenfeld.2021"></a>Wiesenfeld H. Pelvic inflammatory disease: treatment in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep.</i> 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34370424">
<a name="34370424"></a>World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; published June 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/34370424/pubmed" id="34370424" target="_blank">34370424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22970604">
<a name="22970604"></a>World Health Organization (WHO). WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61, 1 p following 61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/22970604/pubmed" id="22970604" target="_blank">22970604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9627517">
<a name="9627517"></a>WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 1998;874:1-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9627517/pubmed" id="9627517" target="_blank">9627517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15252190">
<a name="15252190"></a>Zacher JL and Givone DM, “False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,” <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15252190/pubmed" id="15252190" target="_blank">15252190</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9892 Version 338.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
